• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Former Naurex team launches spin-out company Aptinyx

Former Naurex team launches spin-out company Aptinyx

September 17, 2015
CenterWatch Staff

Aptinyx, a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in Aug. 2015.

Aptinyx has initiated IND-enabling studies for lead candidates stemming from its robust pipeline of small-molecule, orally bioavailable NMDA receptor modulators. The company plans to identify and develop therapeutic candidates that demonstrate differentiated benefits in challenging brain and nervous system disorders, such as traumatic brain injury, neuropathic pain, post-traumatic stress disorder and epilepsy.

Aptinyx's therapeutics are designed to enhance synaptic plasticity, or strengthen the network for neural cell communication, a pathway that underlies multiple nervous system conditions. Therapeutics that modulate NMDA receptors—rather than shut them down—are both highly effective and well-tolerated. The platform was developed based on research from the laboratory of Joseph Moskal, Ph.D., distinguished professor of biomedical engineering at Northwestern University, director of the university's Falk Center for Molecular Therapeutics, founder of Naurex, and chief scientific officer of Aptinyx.

Aptinyx will collaborate with Allergan on the discovery and preclinical development of innovative, orally bioavailable, small-molecule NMDA receptor modulators for the treatment of certain psychiatric and neurologic disorders. Allergan receives the right to in-license a select number of compounds discovered and profiled during the term of the collaboration for certain target indications.

Dr. Riedel was president and CEO of Naurex and remains at the helm of the new spin-out company, Aptinyx. Prior to joining Naurex in Jan. 2014, he was corporate vice president and chief science and innovation officer at Baxter International.

Dr. Moskal founded Naurex and served as its chief scientific officer. He continues in that role at Aptinyx.

Aptinyx has appointed Ashish Khanna to the position of chief business officer. Khanna was vice president of corporate development at Naurex and managed the company's financing and transaction efforts, culminating in the acquisition by Allergan.

Aptinyx also has appointed Torsten Madsen, M.D., Ph.D., as its new chief medical officer. Madsen recently joined Naurex after serving as an observer on the company's board of directors. He previously held numerous positions at H. Lundbeck, including chief medical officer and vice president of U.S. drug development and divisional director of international clinical research in mood and anxiety disorders.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing